Vaccine against tuberculosis: a view

References

1. Achkar J. M., Casadevall A. 2013; Antibody-mediated immunity against tuberculosis: implications for vaccine development. Cell Host Microbe 13:250–262 [View Article][PubMed]
   [Google Scholar]
2. Andersen P., Doherty T. M. 2005; The success and failure of BCG – implications for a novel tuberculosis vaccine. Nat Rev Microbiol 3:656–662 [View Article][PubMed]
   [Google Scholar]
3. Andrews J. R., Noubary F., Walensky R. P., Cerda R., Losina E., Horsburgh C. R. 2012; Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis . Clin Infect Dis 54:784–791 [View Article][PubMed]
   [Google Scholar]
4. Baena A., Porcelli S. A. 2009; Evasion and subversion of antigen presentation by Mycobacterium tuberculosis . Tissue Antigens 74:189–204 [View Article][PubMed]
   [Google Scholar]
5. Barnes P. F., Samten B., Shams H., Vankayalapatib R. 2009; Progress in understanding the human immune responses to Mycobacterium tuberculosis . Tuberculosis (Edinb) 89:Suppl 1S5–S9 [View Article][PubMed]
   [Google Scholar]
6. Colditz G. A., Brewer T. F., Berkey C. S., Wilson M. E., Burdick E., Fineberg H. V., Mosteller F. 1994; Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271:698–702 [View Article][PubMed]
   [Google Scholar]
7. Cooper A. M. 2009; Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 27:393–422 [View Article][PubMed]
   [Google Scholar]
8. del Mar Casal M., Casal M. 2011; Immune response to mycobacteria. Curr Immunol Rev 7:13–18 [View Article]
   [Google Scholar]
9. Falzon D., Jaramillo E., Schünemann H. J., Arentz M., Bauer M., Bayona J., Blanc L., Caminero J. A., Daley C. L. other authors 2011; WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 38:516–528 [View Article][PubMed]
   [Google Scholar]
10. Gupta A., Kaul A., Tsolaki A. G., Kishore U., Bhakta S. 2012; Mycobacterium tuberculosis: immune evasion, latency and reactivation. Immunobiology 217:363–374 [View Article][PubMed]
    [Google Scholar]
11. Harries A. D., Zachariah R., Corbett E. L., Lawn S. D., Santos-Filho E. T., Chimzizi R., Harrington M., Maher D., Williams B. G., De Cock K. M. 2010; The HIV-associated tuberculosis epidemic–when will we act?. Lancet 375:1906–1919 [View Article][PubMed]
    [Google Scholar]
12. Jensen P. E. 2007; Recent advances in antigen processing and presentation. Nat Immunol 8:1041–1048 [View Article][PubMed]
    [Google Scholar]
13. Jereb J., Etkind S. C., Joglar O. T., Moore M., Taylor Z. 2003; Tuberculosis contact investigations: outcomes in selected areas of the United States, 1999. Int J Tuberc Lung Dis 7:Suppl 3S384–S390[PubMed]
    [Google Scholar]
14. Kaufmann S. H. 2013; Tuberculosis vaccines: time to think about the next generation. Semin Immunol 25:172–181 [View Article][PubMed]
    [Google Scholar]
15. Kaufmann S. H., Hussey G., Lambert P. H. 2010; New vaccines for tuberculosis. Lancet 375:2110–2119 [View Article][PubMed]
    [Google Scholar]
16. Lanzavecchia A., Sallusto F. 2005; Understanding the generation and function of memory T cell subsets. Curr Opin Immunol 17:326–332 [View Article][PubMed]
    [Google Scholar]
17. Scherr N., Jayachandran R., Mueller P., Pieters J. 2009; Interference of Mycobacterium tuberculosis with macrophage responses. Indian J Exp Biol 47:401–406[PubMed]
    [Google Scholar]
18. Tameris M. D., Hatherill M., Landry B. S., Scriba T. J., Snowden M. A., Lockhart S., Shea J. E., McClain J. B., Hussey G. D. other authors 2013; Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 381:1021–1028 [View Article][PubMed]
    [Google Scholar]
19. Trombetta E. S., Mellman I. 2005; Cell biology of antigen processing in vitro and in vivo . Annu Rev Immunol 23:975–1028 [View Article][PubMed]
    [Google Scholar]
20. Tung Y. C., Ou T. T., Tsai W. C. 2013; Defective Mycobacterium tuberculosis antigen presentation by monocytes from tuberculosis patients. Int J Tuberc Lung Dis 17:1229–1234 [View Article][PubMed]
    [Google Scholar]
21. Velayati A. A., Farnia P., Masjedi M. R., Ibrahim T. A., Tabarsi P., Haroun R. Z., Kuan H. O., Ghanavi J., Farnia P., Varahram M. 2009; Totally drug-resistant tuberculosis strains: evidence of adaptation at the cellular level. Eur Respir J 34:1202–1203 [View Article][PubMed]
    [Google Scholar]
22. WHO 2013 Global Tuberculosis Report 2013 Geneva, Switzerland: World Health Organization; Available at http://www.who.int/tb/publications/global_report/en/
    [Google Scholar]
23. Wolf A. J., Linas B., Trevejo-Nuñez G. J., Kincaid E., Tamura T., Takatsu K., Ernst J. D. 2007; Mycobacterium tuberculosis infects dendritic cells with high frequency and impairs their function in vivo . J Immunol 179:2509–2519[PubMed] [CrossRef]
    [Google Scholar]
24. Yoshikai Y. 2006; Immunological protection against Mycobacterium tuberculosis infection. Crit Rev Immunol 26:515–526 [View Article][PubMed]
    [Google Scholar]
25. Zignol M., van Gemert W., Falzon D., Sismanidis C., Glaziou P., Floyd K., Raviglione M. 2012; Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007–2010. Bull World Health Organ 90:111–119 [View Article][PubMed]
    [Google Scholar]
26. Zwerling A., Behr M. A., Verma A., Brewer T. F., Menzies D., Pai M. 2011; The BCG World Atlas: a database of global BCG vaccination policies and practices. PLoS Med 8:e1001012 [View Article][PubMed]
    [Google Scholar]